TY - JOUR
T1 - Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study
AU - Benfield, Thomas
AU - Bodilsen, Jacob
AU - Brieghel, Christian
AU - Harboe, Zitta Barrella
AU - Helleberg, Marie
AU - Holm, Claire
AU - Israelsen, Simone Bastrup
AU - Jensen, Janne
AU - Jensen, Tomas Østergaard
AU - Johansen, Isik Somuncu
AU - Johnsen, Stine
AU - Madsen, Birgitte Lindegaard
AU - Lundgren, Jens
AU - Meyer, Christian Niels
AU - Mohey, Rajesh
AU - Pedersen, Lars Møller
AU - Nielsen, Henrik
AU - Nielsen, Stig Lønberg
AU - Obel, Niels
AU - Omland, Lars Haukali
AU - Podlekareva, Daria
AU - Poulsen, Birgitte Klindt
AU - Ravn, Pernille
AU - Sandholdt, Haakon
AU - Starling, Jonathan
AU - Storgaard, Merete
AU - Søborg, Christian
AU - Søgaard, Ole Schmeltz
AU - Tranborg, Torben
AU - Wiese, Lothar
AU - Christensen, Hanne Rolighed
N1 - © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Correction to this articles has been published:
Clinical Infectious Diseases, Volume 74, Issue 10, 15 May 2022, Page 1889, https://doi.org/10.1093/cid/ciac243
PY - 2021/12/6
Y1 - 2021/12/6
N2 - BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).RESULTS: The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38-.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29-.46).CONCLUSIONS: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.
AB - BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).RESULTS: The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38-.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29-.46).CONCLUSIONS: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.
KW - COVID-19
KW - dexamethasone
KW - pneumonia
KW - remdesivir
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85122546522&partnerID=8YFLogxK
U2 - 10.1093/cid/ciab536
DO - 10.1093/cid/ciab536
M3 - Journal article
C2 - 34111274
SN - 1058-4838
VL - 73
SP - 2031
EP - 2036
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
M1 - ciab536
ER -